Related Experiment Video
Updated: Dec 3, 2025

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
In silico Analysis of Pasteurella multocida PlpE Protein Epitopes As Novel Subunit Vaccine Candidates
Saied Mostaan1, Abbas Ghasemzadeh1, Parastoo Ehsani1
1Molecular Biology Department, Pasteur Institute of Iran, Tehran, Iran.
Background:
Pasteurella multocida is a Gram-negative, non-motile, non-spore forming, and aerobic/anaerobic cocobacillus known as the causative agent of human and animal diseases. Humans can often be affected by cat scratch or bite, which may lead to soft tissue infections and in rare cases to bacteremia and septicemia. Commercial vaccines against this agent include inactivated, live attenuated, and non-pathogenic bacteria. Current vaccines have certain disadvantages such as reactogenicity or reversion to virulence. Therefore, the aim of this study was to reach a multi-epitope vaccine candidate that could be serotype independent and covers most incident serotypes of P. multocida.
Methods:
In this study, reverse vaccinology strategy was used to identify potentially immunogenic and protective epitopes. First, multiple alignments of different sequences of Pasteurella lipoprotein E (PlpE) from various serotypes of P. multocida were analyzed to identify the conserved regions. Bioinformatics tools were then applied to predict and select epitopes for further studies.
Results:
Three different conserved immunogenic regions were selected according to the selected criteria, and their various sequential orders were evaluated structurally by in silico tools to find the best order.
Conclusion:
In searching the epitopes of PlpE to design a new vaccine candidate against pasteurellosis, we found the region 1 + region 2 + region 3 (without any linker between regions) of epitope, including the regions of PlpE protein of P. multocida, as the appropriate serotype independent vaccine candidate against pasteurellosis.
Insights
A novel multi-epitope vaccine candidate targeting Pasteurella multocida was developed using reverse vaccinology. This serotype-independent approach identifies conserved regions of the PlpE protein for enhanced protection against pasteurellosis.
Area of Science:
- Veterinary immunology
- Bacteriology
- Vaccine development
Background:
- Pasteurella multocida causes significant human and animal diseases, including soft tissue infections and septicemia.
- Current vaccines for P. multocida have limitations like reactogenicity and potential reversion to virulence.
- There is a need for a serotype-independent vaccine to broaden protection against diverse P. multocida strains.
Purpose of the Study:
- To design a novel, serotype-independent vaccine candidate against Pasteurella multocida.
- To identify conserved immunogenic epitopes from the P. multocida PlpE protein.
- To evaluate different epitope combinations for optimal vaccine design.
Main Methods:
- Employed a reverse vaccinology strategy to identify potential vaccine epitopes.
- Analyzed conserved regions of Pasteurella lipoprotein E (PlpE) from various P. multocida serotypes.
- Utilized bioinformatics tools for epitope prediction and in silico structural evaluation.
Main Results:
- Identified three conserved immunogenic regions within the PlpE protein.
- Evaluated various sequential arrangements of these regions using in silico structural analysis.
- Determined the optimal epitope combination for a vaccine candidate.
Conclusions:
- The combination of region 1 + region 2 + region 3 of PlpE, without linkers, represents a promising serotype-independent vaccine candidate.
- This multi-epitope approach offers a potential solution to overcome limitations of current P. multocida vaccines.
- The identified epitopes provide a foundation for developing effective vaccines against pasteurellosis.
More Related Videos
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022